Trevena Inc. (NASDAQ:TRVN) has been assigned a $14.00 target price by equities researchers at Brean Capital in a research report issued to clients and investors on Monday. The brokerage presently has a a “buy” rating on the biopharmaceutical company’s stock. Brean Capital’s price target would suggest a potential upside of 110.84% from the stock’s previous close.

Other analysts also recently issued reports about the stock. Cowen and Company reaffirmed a “buy” rating and issued a $13.00 target price on shares of Trevena in a research report on Friday, August 5th. FBR & Co reaffirmed a “buy” rating and issued a $13.00 target price on shares of Trevena in a research report on Thursday, August 4th. Zacks Investment Research raised shares of Trevena from a “sell” rating to a “hold” rating in a research report on Wednesday, July 20th. Jefferies Group reaffirmed a “buy” rating on shares of Trevena in a research report on Friday, August 5th. Finally, TheStreet downgraded shares of Trevena from a “hold” rating to a “sell” rating in a research report on Friday, June 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $14.30.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ:TRVN) traded down 1.63% during trading on Monday, hitting $6.64. 187,961 shares of the stock traded hands. The company’s market cap is $346.46 million. The firm has a 50-day moving average price of $6.99 and a 200 day moving average price of $7.22. Trevena has a 52-week low of $5.58 and a 52-week high of $13.02.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by $0.01. Trevena had a negative return on equity of 45.01% and a negative net margin of 841.00%. On average, equities analysts expect that Trevena will post ($1.55) EPS for the current year.

A number of institutional investors have recently bought and sold shares of TRVN. ProShare Advisors LLC boosted its position in Trevena by 6.8% in the second quarter. ProShare Advisors LLC now owns 44,312 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,824 shares in the last quarter. National Planning Corp boosted its position in Trevena by 21.9% in the first quarter. National Planning Corp now owns 19,452 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 3,500 shares in the last quarter. Nationwide Fund Advisors boosted its position in Trevena by 13.3% in the second quarter. Nationwide Fund Advisors now owns 69,297 shares of the biopharmaceutical company’s stock valued at $437,000 after buying an additional 8,142 shares in the last quarter. Rhumbline Advisers boosted its position in Trevena by 34.9% in the second quarter. Rhumbline Advisers now owns 41,901 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 10,849 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its position in Trevena by 54.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 35,964 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 12,694 shares in the last quarter. Institutional investors and hedge funds own 75.43% of the company’s stock.

About Trevena

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Stock Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related stocks with our FREE daily email newsletter.